FDA Panel Weighs Leukemia Gene-Therapy Treatment

A group of cancer experts started weighing Wednesday whether to recommend U.S. regulatory approval for a first-of-its kind gene therapy targeting an aggressive form of leukemia that occurs in children and young adults.

The treatment, called CTL019 and developed by Swiss drug giant Novartis AG, works by modifying a patient's own immune cells to make them more effective at hunting down and killing tumor cells. It involves removing some of the patient's blood and genetically modifying the T-cells, a type of immune cell, before re-infusion.

A Food and Drug Administration advisory committee, which comprises a group of cancer experts from across the U.S., will determine whether the benefits of the therapy outweigh the risks. The committee is expected to announce its decision late Wednesday.

The FDA isn't required to follow the advice of such advisory panels, but it generally does so. Analysts expect the FDA to issue a final decision by the end of September.

The drug holds out the promise of a significant advance in the treatment of children and young adults with a form of blood cancer known as B-cell acute lymphoblastic leukemia. It is also the first in a series of new treatments using genetically modified T-cells facing FDA review.

For Novartis, a thumbs-up would open a potentially big, new revenue stream. Jefferies analysts estimate the drug could bring in $850 million in annual sales by 2021.

Novartis has said that in a clinical trial, 52 of 63 participants who received the treatment were cancer-free after three months. The patients in the study had either failed to respond to standard therapies, or relapsed.

Most children and young adults with this form of leukemia are treated using existing methods such as chemotherapy, radiotherapy and bone marrow transplants.

But the roughly one-in-seven patients who don't respond to standard treatment, or suffer a relapse, have typically had only a 10% to 20% chance of survival, according to Rajesh Chopra, head of cancer therapeutics at the Institute of Cancer Research in London. The Novartis therapy increases that to around 80%. "That's big," he said. Dr. Chopra isn't involved in the study.

CTL019 is the first of a hotly anticipated class of treatments known as CAR-T therapies, all of which use genetically modified T-cells, to be reviewed by the FDA. Hot on its heels is California biotech Kite Pharma Inc., which filed its own CAR-T for non-Hodgkin lymphoma with the FDA just days after Novartis.

Despite their promise, CAR-T therapies have also raised safety concerns.

Seattle, Wash.-based Juno Therapeutics Inc. dropped its most advanced CAR-T candidate earlier this year after several patient deaths during a clinical trial.

A spokesman for Juno said the company had conducted an exhaustive investigation into the causes of the deaths, which appeared to be linked to a mix of the specific design of the treatment, the characteristics of the patients and the process used to administer the therapy. The company plans to release the detailed results of its investigation at a scientific conference later this year, he said.

He added that patients in an early-stage trial for its now-leading product, JCAR017, experienced relatively low rates of serious side effects.

A common side effect of CAR-T therapy is a condition known as cytokine release syndrome, which causes severe flulike symptoms. Novartis said most patients in its trial suffered some form of CRS, but that none died from it.

The FDA, in briefing documents issued ahead of Wednesday's panel meeting, also said there was a risk that CAR-T therapy could, in the long term, make the modified T-cells cancerous.

That caution arises from an incident in the late 2000s when several people developed a leukemia-like condition around 10 years after receiving an older form of gene therapy for an immunodeficiency disease. So far, there is no evidence that a similar effect could occur with the Novartis therapy, which uses a different form of virus to insert the new genetic material.

Xiaobin Victor Lu, gene therapy product reviewer at the FDA, said during the hearing that the design of the Novartis therapy lowered the chances of such a side effect, but that the risk "cannot be entirely eliminated."

Write to Denise Roland at Denise.Roland@wsj.com

A group of cancer experts voted unanimously on Wednesday to support U.S. regulatory approval for a first-of-its kind gene therapy targeting an aggressive form of leukemia that occurs in children and young adults.

The treatment, called CTL019 and developed by Swiss drug company Novartis AG, works by modifying a patient's own immune cells to make them more effective at hunting down and killing tumor cells. It involves removing some of the patient's blood and genetically modifying the T-cells, a type of immune cell, before re-infusion.

A Food and Drug Administration advisory committee, which comprises a group of cancer experts from across the U.S., voted 10 to 0 that the therapy had a favorable risk-benefit balance, meaning that its positive effects outweigh its safety risks. The question of risk-benefit balance is widely seen as a proxy for whether the FDA should approve the treatment.

"This is a major advance and is ushering in a new era of treating children with" severe leukemia, said committee member Malcolm A. Smith, who is associate branch chief for pediatric oncology at the National Cancer Institute.

The FDA isn't required to follow the advice of such advisory panels, but it generally does so. Analysts expect the FDA to issue a final decision by the end of September.

The therapy holds out the promise of a significant advance in the treatment of children and young adults with a form of blood cancer known as B-cell acute lymphoblastic leukemia. It is also the first in a series of new treatments facing FDA review that use genetically modified T-cells.

For Novartis, FDA approval would open a potentially big, new revenue stream. Jefferies analysts estimate the therapy could bring in $850 million in annual sales by 2021.

Most children and young adults with this form of leukemia are treated using existing methods such as chemotherapy, radiotherapy and bone-marrow transplants.

But the roughly 1 in 7 patients who don't respond to standard treatment, or suffer a relapse, have typically had only a 10% to 20% chance of survival, according to Rajesh Chopra, head of cancer therapeutics at the Institute of Cancer Research in London. The Novartis therapy raises that to about 80%. "That's big," he said. Dr. Chopra isn't involved in the study.

Timothy P. Cripe, an advisory committee member and pediatric oncologist, said the Novartis therapy was "the most exciting thing I've seen in my lifetime and probably since" advances in the treatment of childhood leukemia in the 1950s.

CTL019 is the first of a hotly anticipated class of treatments known as CAR-T therapies, all of which use genetically modified T-cells, to be reviewed by the FDA. Close behind is California biotech Kite Pharma Inc., which filed its own CAR-T for non-Hodgkin lymphoma with the FDA just days after Novartis.

Despite their promise, CAR-T therapies have also raised safety concerns.

Seattle-based Juno Therapeutics Inc. dropped its most advanced CAR-T candidate earlier this year after several patient deaths during a clinical trial due to swelling in the brain.

He added that patients in an early-stage trial for its now-leading product, JCAR017, experienced relatively low rates of serious side effects.

The FDA, in briefing documents issued ahead of Wednesday's panel meeting, also said there was a risk that CAR-T therapy could, in the long term, make the modified T-cells cancerous.

That caution arises from an incident in the late 2000s when several people developed a leukemia-like condition about 10 years after receiving an older form of gene therapy for an immunodeficiency disease. So far, there is no evidence that a similar effect could occur with the Novartis therapy, which uses a different form of virus to insert the new genetic material.

Xiaobin Victor Lu, gene-therapy product reviewer at the FDA, said during the hearing that the design of the Novartis therapy lowered the chances of such a side effect, but that the risk "cannot be entirely eliminated."

To help address these concerns, Novartis has said it would monitor clinical trial patients for 15 years and would set up a registry of patients who receive the therapy post-approval to monitor for unexpected side effects.

Write to Denise Roland at Denise.Roland@wsj.com

(END) Dow Jones Newswires

July 12, 2017 16:39 ET (20:39 GMT)